AEZS

Aeterna Zentaris
AEZS

$5.35

0.93%

Market Cap: 16.4M

About: AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of significant unmet medical need. One of Aeterna's lead products is macimorelin (Macrilen; Ghryvelin), the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources currently used in cosmeceutical products and being developed as potential nutraceuticals and/or pharmaceuticals.

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

62% more capital invested

Capital invested by funds: $65.2K [Q4 2023] → $106K (+$40.4K) [Q1 2024]

0.28% more ownership

Funds ownership: 0.73% [Q4 2023] → 1.0% (+0.28%) [Q1 2024]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

15% less funds holding

Funds holding: 13 [Q4 2023] → 11 (-2) [Q1 2024]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for AEZS.

See Analyst Rankings

Financial journalist opinion

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the "AGSM") held today.

Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announced the clinical completion of its Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency ("CGHD"). The Company confirms that the last patient conducted the last study visit successfully in Europe on June 13, 2024.

Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders

MILWAUKEE , June 7, 2024 /PRNewswire/ -- Ademi LLP is investigating Aeterna (Nasdaq: AEZS) for possible breaches of fiduciary duty and other violations of law in its transaction with Ceapro. Click here to learn how to join our investigation: https://www.ademilaw.com/case/aeterna-zentaris-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders

Aeterna Zentaris and Ceapro Complete Merger Transaction

TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce the successful completion and closing of their all-stock merger of equals transaction (the “Transaction”), which was previously announced by Aeterna and Ceapro in their joint press release of December 14, 2023.

Aeterna Zentaris and Ceapro Complete Merger Transaction

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that it is making an application for an order pursuant to section 133(3) of the Canada Business Corporations Act extending the time for the Company to call and hold its annual meeting of its shareholders to a date that is not later than July 31, 2024 (the “Application”). The Application is scheduled to be heard before a judge of the Ontario Superior Court of Justice, Commercial List (the “Court”) on June 3, 2024 at 11:00 a.m. via videoconference. There can be no assurance that the order sought by Aeterna will be granted.

Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “Transaction”) with Ceapro Inc. (“Ceapro”).

Aeterna Zentaris Announces Details Regarding Transaction with Ceapro

Aeterna Zentaris Reports First Quarter 2024 Financial Results

TORONTO, ONTARIO, May 14, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the quarter ended March 31, 2024.

Aeterna Zentaris Reports First Quarter 2024 Financial Results

Aeterna Zentaris Announces Effective Date of Share Consolidation

TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has filed articles of amendment to effect the previously announced share consolidation (or reverse stock split) (the “Consolidation”) of its issued and outstanding common shares (the “Common Shares”) on the basis of one post-Consolidation Common Share for every four pre-Consolidation Common Shares.

Aeterna Zentaris Announces Effective Date of Share Consolidation

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”).

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Zacks Investment Research

Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates

Aeterna Zentaris (AEZS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $0.84 per share a year ago.

Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates

See News Rankings